New hope for brain cancer: Immune-Boosting combo targets glioblastoma
NCT ID NCT03491683
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This early-stage trial tests whether adding two experimental DNA vaccines (INO-5401 and INO-9012) and an immunotherapy drug (cemiplimab) to standard radiation and chemotherapy can help people with newly-diagnosed glioblastoma, an aggressive brain cancer. The study enrolls 52 participants and primarily checks safety, while also looking at survival and immune system changes. Because glioblastoma often returns and requires ongoing management, this approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
City of Hope
Duarte, California, 91010, United States
-
Columbia University Medical Center The Neurological Institute of New York
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Langone Medical Center; Perlmutter Cancer Center
New York, New York, 10016, United States
-
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Rutgers University - Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Stanford University, School of Medicine
Palo Alto, California, 94304, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Texas Oncology
Austin, Texas, 78705, United States
-
UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion
Pittsburgh, Pennsylvania, 15232, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina School of Medicine
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania Health System: Penn Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.